Cell Death Induction in Cancer Therapy - Past, Present, and Future

Lisa Nonnenmacher, Sebastian Hasslacher, Julia Zimmermann, Georg Karpel-Massler, Katia La Ferla-Brühl, Sara E Barry, Timo Burster, Markus D Siegelin, Oliver Brühl, Marc-Eric Halatsch, Klaus-Michael Debatin, Mike-Andrew Westhoff

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The induction of apoptosis, a physiological type of cell death, is currently the primary therapeutic aim of most cancer therapies. As resistance to apoptosis is an early hallmark of developing cancer, the success of this treatment strategy is already potentially compromised at treatment initiation. In this review, we discuss the tumor in Darwinian terms and describe it as a complex, yet highly unstable, ecosystem. Current therapeutic strategies often focus on directly killing the dominant subclone within the population of mutated cancer cells while ignoring the subclonal complexity within the ecosystem tumor, the complexity of the direct tumor/ microenvironment interaction and the contribution of the ecosystem human - that is, the global environment which provides the tumor with both support and challenges. The Darwinian view opens new possible therapeutic interventions, such as the disruption of the microenvironment by targeting nonmutated cells within the tumor or the interaction points of mutant tumor cells with their environment, and it forces us to reevaluate therapeutic endpoints. It is our belief that a central future challenge of apoptosis-inducing therapies will be to understand better under which preconditions which treatment strategy and which therapeutic endpoint will lead to the highest quality and quantity of a patient's life.

Original languageEnglish
Pages (from-to)253-267
Number of pages15
JournalCritical Reviews in Oncogenesis
Volume21
Issue number3-4
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Cell Death
Neoplasms
Ecosystem
Therapeutics
Apoptosis
Tumor Microenvironment
Population

Keywords

  • Animals
  • Antineoplastic Agents
  • Apoptosis
  • Humans
  • Mutation Accumulation
  • Neoplasms
  • Tumor Microenvironment
  • Journal Article
  • Review

Cite this

Nonnenmacher, L., Hasslacher, S., Zimmermann, J., Karpel-Massler, G., La Ferla-Brühl, K., Barry, S. E., ... Westhoff, M-A. (2016). Cell Death Induction in Cancer Therapy - Past, Present, and Future. Critical Reviews in Oncogenesis, 21(3-4), 253-267. https://doi.org/10.1615/CritRevOncog.2016016987

Cell Death Induction in Cancer Therapy - Past, Present, and Future. / Nonnenmacher, Lisa; Hasslacher, Sebastian; Zimmermann, Julia; Karpel-Massler, Georg; La Ferla-Brühl, Katia; Barry, Sara E; Burster, Timo; Siegelin, Markus D; Brühl, Oliver; Halatsch, Marc-Eric; Debatin, Klaus-Michael; Westhoff, Mike-Andrew.

In: Critical Reviews in Oncogenesis, Vol. 21, No. 3-4, 2016, p. 253-267.

Research output: Contribution to journalReview article

Nonnenmacher, L, Hasslacher, S, Zimmermann, J, Karpel-Massler, G, La Ferla-Brühl, K, Barry, SE, Burster, T, Siegelin, MD, Brühl, O, Halatsch, M-E, Debatin, K-M & Westhoff, M-A 2016, 'Cell Death Induction in Cancer Therapy - Past, Present, and Future', Critical Reviews in Oncogenesis, vol. 21, no. 3-4, pp. 253-267. https://doi.org/10.1615/CritRevOncog.2016016987
Nonnenmacher L, Hasslacher S, Zimmermann J, Karpel-Massler G, La Ferla-Brühl K, Barry SE et al. Cell Death Induction in Cancer Therapy - Past, Present, and Future. Critical Reviews in Oncogenesis. 2016;21(3-4):253-267. https://doi.org/10.1615/CritRevOncog.2016016987
Nonnenmacher, Lisa ; Hasslacher, Sebastian ; Zimmermann, Julia ; Karpel-Massler, Georg ; La Ferla-Brühl, Katia ; Barry, Sara E ; Burster, Timo ; Siegelin, Markus D ; Brühl, Oliver ; Halatsch, Marc-Eric ; Debatin, Klaus-Michael ; Westhoff, Mike-Andrew. / Cell Death Induction in Cancer Therapy - Past, Present, and Future. In: Critical Reviews in Oncogenesis. 2016 ; Vol. 21, No. 3-4. pp. 253-267.
@article{9ef1cd2dfac7473582ecd298b418fe1a,
title = "Cell Death Induction in Cancer Therapy - Past, Present, and Future",
abstract = "The induction of apoptosis, a physiological type of cell death, is currently the primary therapeutic aim of most cancer therapies. As resistance to apoptosis is an early hallmark of developing cancer, the success of this treatment strategy is already potentially compromised at treatment initiation. In this review, we discuss the tumor in Darwinian terms and describe it as a complex, yet highly unstable, ecosystem. Current therapeutic strategies often focus on directly killing the dominant subclone within the population of mutated cancer cells while ignoring the subclonal complexity within the ecosystem tumor, the complexity of the direct tumor/ microenvironment interaction and the contribution of the ecosystem human - that is, the global environment which provides the tumor with both support and challenges. The Darwinian view opens new possible therapeutic interventions, such as the disruption of the microenvironment by targeting nonmutated cells within the tumor or the interaction points of mutant tumor cells with their environment, and it forces us to reevaluate therapeutic endpoints. It is our belief that a central future challenge of apoptosis-inducing therapies will be to understand better under which preconditions which treatment strategy and which therapeutic endpoint will lead to the highest quality and quantity of a patient's life.",
keywords = "Animals, Antineoplastic Agents, Apoptosis, Humans, Mutation Accumulation, Neoplasms, Tumor Microenvironment, Journal Article, Review",
author = "Lisa Nonnenmacher and Sebastian Hasslacher and Julia Zimmermann and Georg Karpel-Massler and {La Ferla-Br{\"u}hl}, Katia and Barry, {Sara E} and Timo Burster and Siegelin, {Markus D} and Oliver Br{\"u}hl and Marc-Eric Halatsch and Klaus-Michael Debatin and Mike-Andrew Westhoff",
year = "2016",
doi = "10.1615/CritRevOncog.2016016987",
language = "English",
volume = "21",
pages = "253--267",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "3-4",

}

TY - JOUR

T1 - Cell Death Induction in Cancer Therapy - Past, Present, and Future

AU - Nonnenmacher, Lisa

AU - Hasslacher, Sebastian

AU - Zimmermann, Julia

AU - Karpel-Massler, Georg

AU - La Ferla-Brühl, Katia

AU - Barry, Sara E

AU - Burster, Timo

AU - Siegelin, Markus D

AU - Brühl, Oliver

AU - Halatsch, Marc-Eric

AU - Debatin, Klaus-Michael

AU - Westhoff, Mike-Andrew

PY - 2016

Y1 - 2016

N2 - The induction of apoptosis, a physiological type of cell death, is currently the primary therapeutic aim of most cancer therapies. As resistance to apoptosis is an early hallmark of developing cancer, the success of this treatment strategy is already potentially compromised at treatment initiation. In this review, we discuss the tumor in Darwinian terms and describe it as a complex, yet highly unstable, ecosystem. Current therapeutic strategies often focus on directly killing the dominant subclone within the population of mutated cancer cells while ignoring the subclonal complexity within the ecosystem tumor, the complexity of the direct tumor/ microenvironment interaction and the contribution of the ecosystem human - that is, the global environment which provides the tumor with both support and challenges. The Darwinian view opens new possible therapeutic interventions, such as the disruption of the microenvironment by targeting nonmutated cells within the tumor or the interaction points of mutant tumor cells with their environment, and it forces us to reevaluate therapeutic endpoints. It is our belief that a central future challenge of apoptosis-inducing therapies will be to understand better under which preconditions which treatment strategy and which therapeutic endpoint will lead to the highest quality and quantity of a patient's life.

AB - The induction of apoptosis, a physiological type of cell death, is currently the primary therapeutic aim of most cancer therapies. As resistance to apoptosis is an early hallmark of developing cancer, the success of this treatment strategy is already potentially compromised at treatment initiation. In this review, we discuss the tumor in Darwinian terms and describe it as a complex, yet highly unstable, ecosystem. Current therapeutic strategies often focus on directly killing the dominant subclone within the population of mutated cancer cells while ignoring the subclonal complexity within the ecosystem tumor, the complexity of the direct tumor/ microenvironment interaction and the contribution of the ecosystem human - that is, the global environment which provides the tumor with both support and challenges. The Darwinian view opens new possible therapeutic interventions, such as the disruption of the microenvironment by targeting nonmutated cells within the tumor or the interaction points of mutant tumor cells with their environment, and it forces us to reevaluate therapeutic endpoints. It is our belief that a central future challenge of apoptosis-inducing therapies will be to understand better under which preconditions which treatment strategy and which therapeutic endpoint will lead to the highest quality and quantity of a patient's life.

KW - Animals

KW - Antineoplastic Agents

KW - Apoptosis

KW - Humans

KW - Mutation Accumulation

KW - Neoplasms

KW - Tumor Microenvironment

KW - Journal Article

KW - Review

U2 - 10.1615/CritRevOncog.2016016987

DO - 10.1615/CritRevOncog.2016016987

M3 - Review article

VL - 21

SP - 253

EP - 267

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 3-4

ER -